Abstract 1878P
Background
The growing number of patients with genitourinary cancers (GU) could create an increasing burden on GU oncologists. Bureau for Cancer Research (BUCARE) describes the prevalence of burnout in GU oncologists in Central Asia region.
Methods
This is a cross-sectional survey study conducted among practicing cancer care physicians (surgical, medical, radiation) at the ASCO / Asian American GU Symposium ( Almaty, April 2023 ). The primary outcome was burnout experience assessed through the Maslach Burnout Inventory.
Results
A total of 101 oncologists completed the questionnaire. Table summarizes physician's characteristics. Despite the fact that 100% of responders are interested in their work, 66% (67 of 101) had symptoms of burnout (high emotional exhaustion and/or depersonalization scores). Fifty percent of oncologists are ready to turn to a psychologist for help. Significant drivers of burnout identified in multivariable regression modeling included ³20 patients per day (odds ratio [OR] = 14.8; P<0.001) and ³10 working hours per day (OR=8.6; P<0.001). Male gender (OR=0.14; P<0.001) and specialization in radiation therapy (OR=0.20; P<0.01) were associated with lower odds of burnout.
Conclusions
More than half of participants met predefined standardized criteria for burnout. Expanding the staff of GU oncologists and reducing the daily workload may improve the emotional state of physicians. Table: 1878P
Characteristics | N=101 |
Gender, N (%) | |
Female | 68 (67.3) |
Male | 33 (37.7) |
Region, N (%) | |
Kazakhstan | 85 (84.2) |
Other countries | 17 (16.8) |
Specialty, N (%) | |
Surgery | 39 (38.6) |
Medical Oncology | 44 (43.6) |
Radiation Oncology | 18 (17.8) |
Department, N (%) | |
In-patient | 79 (78.2) |
Out-patient | 22 (21.8) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1877P - Meaning-making in the re-entry phase: A qualitative focus group study with patients with breast cancer and melanoma
Presenter: Anna Visser
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05